Remune: IMNR will begin this month a Phase III U.S. trial of its immune-based therapy

Patients with CD4 counts of 300-550 will be given 100 µg of drug once every three months intramuscularly for up to three years. The end point of the trial will be time to the first AIDS-defining event. CD4 counts and viral load also will be monitored. ...